Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secon...

Bibliografiset tiedot
Päätekijät:	Cavenaugh, J, Awi, D, Mendy, M, Hill, A, Whittle, H, McConkey, S
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Public Library of Science 2011

Samankaltaisia teoksia

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
Tekijä: James S Cavenaugh, et al.
Julkaistu: (2011-02-01)

Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.
Tekijä: McConkey, S, et al.
Julkaistu: (2004)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
Tekijä: McConkey, S, et al.
Julkaistu: (2003)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
Tekijä: Gilbert, S, et al.
Julkaistu: (2006)

Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians
Tekijä: Mendy, M, et al.
Julkaistu: (2006)

Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia
Tekijä: Waight Pauline A, et al.
Julkaistu: (2006-04-01)

DNA/MVA Vaccines for HIV/AIDS
Tekijä: Smita S. Iyer, et al.
Julkaistu: (2014-02-01)

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia
Tekijä: Crozier Sarah, et al.
Julkaistu: (2008-04-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
Tekijä: Hanke, T, et al.
Julkaistu: (2002)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Tekijä: Moorthy, V, et al.
Julkaistu: (2004)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Tekijä: Vasee S Moorthy, et al.
Julkaistu: (2004-11-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Tekijä: De Barra, E, et al.
Julkaistu: (2014)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
Tekijä: Ye Zheng, et al.
Julkaistu: (2022-01-01)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis
Tekijä: Ryckman, K, et al.
Julkaistu: (2010)

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
Tekijä: Tamara Kusay Jabbar, et al.
Julkaistu: (2013-01-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
Tekijä: Lynette Siv Chea, et al.
Julkaistu: (2017-10-01)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
Tekijä: Joan Kha-Tu Ho, et al.
Julkaistu: (2020-01-01)

Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy
Tekijä: Scognamiglio Paola, et al.
Julkaistu: (2009-06-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians
Tekijä: Yindom, L, et al.
Julkaistu: (2017)

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine
Tekijä: Yu-Min Choi, et al.
Julkaistu: (2023-06-01)

Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.
Tekijä: Mendy, M, et al.
Julkaistu: (2010)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
Tekijä: Rollier, C, et al.
Julkaistu: (2016)

Therapeutic vaccines in HBV: lessons from HCV
Tekijä: Barnes, E
Julkaistu: (2015)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis.
Tekijä: Kelli K Ryckman, et al.
Julkaistu: (2010-08-01)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
Tekijä: Eoghan de Barra, et al.
Julkaistu: (2014-01-01)

Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus.
Tekijä: Mendy, M, et al.
Julkaistu: (2008)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
Tekijä: Wyatt LS, et al.
Julkaistu: (2009-10-01)

Correction: Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis.
Tekijä: Kelli K. Ryckman, et al.
Julkaistu: (2011-01-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
Tekijä: Louis-Marie Yindom, et al.
Julkaistu: (2017-01-01)

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model
Tekijä: Dorien De Pooter, et al.
Julkaistu: (2024-02-01)

Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-naïve chronic hepatitis B virus infection
Tekijä: Kun-yan Hao, et al.
Julkaistu: (2025-01-01)

Quantification of hepatitis B virus (HBV) DNA and HBV genotyping simultaneously in plasma using real-time polymerase chain reaction
Tekijä: Woottichai Khamduang, et al.
Julkaistu: (2018-08-01)

Virological profiles of hepatitis B virus (HBV)-infected African patients treated with tenofovir
Tekijä: H.F. Njai, et al.
Julkaistu: (2014-04-01)

A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review
Tekijä: Mokaya, J, et al.
Julkaistu: (2018)

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
Tekijä: Qiyao Wei, et al.
Julkaistu: (2025-02-01)

Mechanisms of Hepatitis B Virus cccDNA and Minichromosome Formation and HBV Gene Transcription
Tekijä: Andoni Gómez-Moreno, et al.
Julkaistu: (2024-04-01)

Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program
Tekijä: Peto, T, et al.
Julkaistu: (2014)

Generation of multivalent recombinant MVA vaccines for malaria
Tekijä: Orubu, T
Julkaistu: (2012)

The impact of hepatitis B virus (HBV) splicing on HBV replication and disease progression
Tekijä: Laura C. McCoullough, et al.
Julkaistu: (2024-08-01)

Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine
Tekijä: Horng-Jyh Tsai
Julkaistu: (2015-04-01)